Coverage
-
November 13, 2012
Alnylam Pharmaceuticals Inc. has agreed to pay $65 million to Tekmira Pharmaceuticals Corp. as part of a licensing agreement settling a lawsuit that accused it of misappropriating Tekmira's trade secrets related to gene-silencing therapeutics, the companies announced Monday.
3 other articles on this case.
View all »